

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LEPU BIOPHARMA CO., LTD.**  
**樂普生物科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2157)**

**AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

References are made to the circular (the “**Circular**”) of Lepu Biopharma Co., Ltd. (the “**Company**”) dated May 24, 2023, regarding the 2022 annual general meeting of the Company (the “**2022 AGM**”) and the poll results announcement of the 2022 AGM of the Company dated June 15, 2023. Unless the context otherwise requires, the terms used in this announcement shall have the same meanings as defined in the Circular.

Pursuant to the General Mandate granted by the 2022 AGM, the Company has issued new H Shares on May 24, 2024. On August 27, 2024, the Company obtained the filing notice issued by the China Security Regulation Commission in relation to the issuance of new H shares. To reflect the new capital structure of the Company and pursuant to the authorization granted by the 2022 AGM to increase the registered capital of the Company after the issuance of additional Shares and to make corresponding amendments to the Articles of Association relating to share capital and shareholdings etc., the amendments to the Articles of Association have been made on September 2, 2024.

The details of the amendments to the Articles of Association are as follows:

**Article 3 reads as follows:**

“As approved by the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on June 24, 2021, the Company has issued 126,876,000 overseas-listed foreign shares (hereinafter referred to as “H Shares”) on the Main Board of the Hong Kong Stock Exchange Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) and 899,000 H Shares upon the exercises of over-allotment on February 23, 2022 and March 22, 2022, respectively.”

It is amended as follows:

“As approved by the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on June 24, 2021, the Company has issued 126,876,000 overseas-listed foreign shares (hereinafter referred to as “H Shares”) on the Main Board of the Hong Kong Stock Exchange Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) and 899,000 H Shares upon the exercises of over-allotment on February 23, 2022 and March 22, 2022, respectively. On May 24, 2024, the Company issued 51,170,000 H Shares by way of placing.”

**Article 5 reads as follows:**

“The registered capital of the Company is RMB1,659,444,838.”

It is amended as follows:

“The registered capital of the Company is RMB1,710,614,838.”

For the full text of the amended Articles of Association, please refer to the websites of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.lepubiopharma.com](http://www.lepubiopharma.com)).

Shareholders should be aware that the English version of the Articles of Association is the translation of the Chinese version. The Chinese version of the Articles of Association shall prevail in the case of any inconsistencies between the two versions.

By order of the Board  
**Lepu Biopharma Co., Ltd.**  
**Dr. Pu Zhongjie**  
*Chairman of the Board and Executive Director*

Shanghai, the PRC  
September 2, 2024

*As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Mr. Yang Hongbing and Ms. Pu Jue as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.*